Australia markets close in 2 hours 8 minutes

Ironwood Pharmaceuticals, Inc. (IRWD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
12.08-0.01 (-0.08%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 51.97B
Enterprise value 31.94B
Trailing P/E 3.86
Forward P/E 17.32
PEG ratio (5-yr expected) 10.14
Price/sales (ttm)4.76
Price/book (mrq)3.84
Enterprise value/revenue 34.70
Enterprise value/EBITDA 78.63

Trading information

Stock price history

Beta (5Y monthly) 1.32
52-week change 320.90%
S&P500 52-week change 334.98%
52-week high 314.27
52-week low 38.63
50-day moving average 313.05
200-day moving average 311.90

Share statistics

Avg vol (3-month) 31.87M
Avg vol (10-day) 31.66M
Shares outstanding 5162.9M
Implied shares outstanding 6N/A
Float 144.01M
% held by insiders 11.41%
% held by institutions 1110.64%
Shares short (30 Aug 2021) 420.89M
Short ratio (30 Aug 2021) 413.63
Short % of float (30 Aug 2021) 424.10%
Short % of shares outstanding (30 Aug 2021) 412.82%
Shares short (prior month 29 July 2021) 420.38M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 June 2021


Profit margin 123.20%
Operating margin (ttm)54.02%

Management effectiveness

Return on assets (ttm)19.22%
Return on equity (ttm)214.30%

Income statement

Revenue (ttm)413.02M
Revenue per share (ttm)2.57
Quarterly revenue growth (yoy)16.30%
Gross profit (ttm)298.32M
EBITDA 224.96M
Net income avi to common (ttm)508.86M
Diluted EPS (ttm)3.13
Quarterly earnings growth (yoy)1,452.50%

Balance sheet

Total cash (mrq)492.7M
Total cash per share (mrq)3.03
Total debt (mrq)464.56M
Total debt/equity (mrq)90.78
Current ratio (mrq)4.62
Book value per share (mrq)3.14

Cash flow statement

Operating cash flow (ttm)227.41M
Levered free cash flow (ttm)137.76M